Contents Link Navigation Link

Targeting, Attacking, and Eradicating Cancers®

Targeting, Attacking, and Eradicating Cancers®

적응증 확대 및 병용치료법 개발

비임상 시험
차세대바이러스
임상 시험 (PEXA-VEC, JX-594)
임상 1상
  • PEXA-VEC + REGN2810(PD-1)**신장암
  • PEXA-VEC + IMFINZI®
    (+ Tremelimumab)대장암
  • nih
  • PEXA-VEC + OPDIVO®간암
  • transgene
  • PEXA-VEC + YERVOY®고형암
  • transgene
  • PEXA-VEC (neoadjuvant)고형암
  • transgene
  • PEXA-VEC + PD-L1**간암
  • pharm
임상 3상
  • PEXA-VEC + NEXAVAR
    vs.
    NEXAVAR
    간암(1L)

www.pexavectrials.com

  • SillaJen-proprietary assets (Unpartnered with full global rights intact)
  • SillaJen is global sponsor
  • Transgene-sponsored study
  • NCI-sponsored study
  • Lee’s Pharma-sponsored study

** Study start expected in 2018